

1  
2  
3  
4

**TITLE PAGE**  
**- Food Science of Animal Resources -**  
**Upload this completed form to website with submission**

ARTICLE INFORMATION	Fill in information in each box below
<b>Article Type</b>	Research article
<b>Article Title</b>	Inhibitory effect of genomic DNA extracted from <i>Pediococcus acidilactici</i> on <i>Porphyromonas gingivalis</i> lipopolysaccharide-induced inflammatory responses
<b>Running Title (within 10 words)</b>	<i>P. acidilactici</i> gDNA inhibits <i>P. gingivalis</i> LPS-induced inflammatory responses
<b>Author</b>	Young Hyeon Choi, Bong Sun Kim, Seok-Seong
<b>Affiliation</b>	Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University, Goyang, 10326, Korea
<b>Special remarks</b> – if authors have additional information to inform the editorial office	None
<b>ORCID (All authors must have ORCID) <a href="https://orcid.org">https://orcid.org</a></b>	Young Hyeon Choi ( <a href="http://orcid.org/0000-0002-4954-7766">http://orcid.org/0000-0002-4954-7766</a> ) Bong Sun Kim ( <a href="https://orcid.org/0000-0001-7676-6238">https://orcid.org/0000-0001-7676-6238</a> ) Seok-Seong Kang ( <a href="https://orcid.org/0000-0001-7029-9122">https://orcid.org/0000-0001-7029-9122</a> )
<b>Conflicts of interest</b> List any present or potential conflicts of interest for all authors. (This field may be published.)	The authors declare no potential conflict of interest.
<b>Acknowledgements</b> State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available. (This field may be published.)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1A2C1010010).
<b>Author contributions</b> (This field may be published.)	Conceptualization: Choi YH, Kim BS, Kang SS. Data curation: Choi YH, Kim BS. Formal analysis: Choi YH, Kim BS. Methodology: Choi YH, Kim BS. Software: Choi YH, Kim BS. Validation: Choi YH, Kim BS. Investigation: Choi YH, Kim BS. Writing - original draft: Choi YH. Writing - review & editing: Choi YH, Kang SS.
<b>Ethics approval (IRB/IACUC)</b> (This field may be published.)	This article does not require IRB/IACUC approval because there are no human and animal participants.

5  
6

**CORRESPONDING AUTHOR CONTACT INFORMATION**

For the <u>corresponding</u> author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Seok-Seong Kang
Email address – this is where your proofs will be sent	sskang@dgu.ac.kr
Secondary Email address	Kangelo72@gmail.com
Postal address	Department of Food Science and Biotechnology, Dongguk University, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10326, Korea
Cell phone number	+82-10-3669-6409
Office phone number	
Fax number	

7

8 **Abstract**

9 This study aimed to assess whether genomic DNA (gDNA) extracted from *Pediococcus*  
10 *acidilactici* inhibits *Porphyromonas gingivalis* lipopolysaccharide (LPS)-induced  
11 inflammatory responses in RAW 264.7 cells. Pretreatment with gDNA of *P. acidilactici* K10  
12 or *P. acidilactici* HW01 for 15 h effectively inhibited *P. gingivalis* LPS-induced mRNA  
13 expression of interleukin (IL)-1 $\beta$ , IL-6, and monocyte chemoattractant protein (MCP)-1.  
14 Although both gDNAs did not dose-dependently inhibit *P. gingivalis* LPS-induced mRNA  
15 expression of IL-6 and MCP-1, they inhibited IL-1 $\beta$  mRNA expression in a dose-dependent  
16 manner. Moreover, pretreatment with both gDNAs inhibited the secretion of IL-1 $\beta$ , IL-6, and  
17 MCP-1. When RAW 264.7 cells were stimulated with *P. gingivalis* LPS alone, the  
18 phosphorylation of mitogen-activated protein kinases (MAPKs) was increased. However, the  
19 phosphorylation of MAPKs was reduced in the presence of gDNAs. Furthermore, both gDNAs  
20 restored I $\kappa$ B $\alpha$  degradation induced by *P. gingivalis* LPS, indicating that both gDNAs  
21 suppressed the activation of nuclear factor- $\kappa$ B (NF- $\kappa$ B). In summary, *P. acidilactici* gDNA  
22 could inhibit *P. gingivalis* LPS-induced inflammatory responses through the suppression of  
23 MAPKs and NF- $\kappa$ B, suggesting that *P. acidilactici* gDNA could be effective in preventing  
24 periodontitis.

25  
26 **Keywords:** *Pediococcus acidilactici*; genomic DNA; *Porphyromonas gingivalis*; Periodontitis;  
27 Inflammation

28

29

## 30 Introduction

31 Probiotics, which mostly consist of lactic acid bacteria, are well known to confer beneficial  
32 effects (Chugh and Kamal-Eldin, 2020). Their physiological functions are beneficial to human  
33 health by inhibiting pathogen adhesion, enhancing the functions of the intestinal epithelial  
34 barrier, and modulating host immune responses (Lebeer et al., 2010). Moreover, the use of  
35 probiotics is a promising therapeutic approach against many inflammatory diseases (Maekawa  
36 and Hajishengallis, 2014). These effects of probiotics can be attributed to the production of  
37 bioactive molecules, such as cell wall components, bacteriocins, short-chain fatty acids,  
38 exopolysaccharides, enzymes, and amino acids (Chugh and Kamal-Eldin, 2020; Lebeer et al.,  
39 2010).

40 In addition to the bioactive molecules of probiotics, their genomic DNA (gDNA) has been  
41 proven to exert probiotic effects. For instance, gDNA extracted from *Lactobacillus plantarum*  
42 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)- $\alpha$  secretion by  
43 suppressing the activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-  
44  $\kappa$ B (NF- $\kappa$ B) in THP-1 cells (Hee Kim et al., 2012). Moreover, oligodeoxynucleotides from *L.*  
45 *casei* gDNA inhibited inflammatory responses in human intestinal epithelial cells *in vitro* as  
46 well as in a dextran sulfate sodium-induced murine colitis model (Hiramatsu et al., 2014). More  
47 recently, gDNA extracted from *L. rhamnosus* GG was found to inhibit LPS-induced interleukin  
48 (IL)-6 production in RAW 264.7 cells (Qi et al., 2020).

49 Periodontitis is defined as a chronic inflammatory oral disease caused by multiple microbial  
50 infections, resulting in the gradual destruction of tissues supporting teeth and the alveolar bone  
51 (Saini et al., 2009). Moreover, periodontitis is known to be associated with systemic diseases,  
52 such as cardiovascular and respiratory diseases, rheumatoid arthritis, and metabolic syndrome

53 (Winning and Linden, 2015). *Porphyromonas gingivalis* is a Gram-negative anaerobic  
54 bacterium that is considered to be the main pathogen responsible for periodontitis by producing  
55 several virulence factors, such as extracellular proteases and LPS (Bostanci and Belibasakis,  
56 2012). Among the bacteria associated with the pathogenesis of periodontitis, *P. gingivalis* has  
57 been extensively studied because of its unique ability to penetrate the gingivae and cause tissue  
58 destruction by inducing inflammation (How et al., 2016).

59 The findings of *in vitro* and *in vivo* analyses have confirmed that probiotics can alleviate  
60 periodontal diseases (Nguyen et al., 2021). However, probiotics need to be viable to perform  
61 their biological functions. Moreover, the use of probiotics may cause some adverse effects,  
62 such as antibiotic resistance and systemic infections in immunocompromised patients (Doron  
63 and Snyderman, 2015). Therefore, molecules with functional bioactivities, also known as  
64 postbiotics, are considered promising alternatives to probiotics. Although the health benefits of  
65 probiotics, particularly lactobacilli, are well known, pediococci also exhibit certain  
66 probiotic effects. Bioactive molecules, such as exopolysaccharides and bacteriocins, of  
67 *Pediococcus acidilactici* exhibit probiotic effects, including antioxidant, lipid-lowering,  
68 antimicrobial, and anti-inflammatory effects (Moon et al., 2014; Seo and Kang, 2020; Song et  
69 al., 2021). In addition, our studies have shown the beneficial effects of postbiotics derived from  
70 *P. acidilactici* K10 and *P. acidilactici* HW01, such as bacteriocin and bacterial lysates.  
71 Bacteriocins of *P. acidilactici* K10 and *P. acidilactici* HW01 inhibit biofilm formation of  
72 foodborne pathogenic bacteria, including *Enterococcus faecalis* and *Pseudomonas aeruginosa*  
73 (Lee et al., 2020; Yoon and Kang, 2020). More recently, bacterial lysates of both *P. acidilactici*  
74 K10 and *P. acidilactici* HW01 exert antibiofilm, anti-adhesive and anti-invasive activities  
75 against *Listeria monocytogenes* (Lee et al., 2022). Therefore, this study aimed to assess the

76 anti-inflammatory effect of gDNA extracted from *P. acidilactici* K10 and *P. acidilactici* HW01  
77 against *P. gingivalis* LPS-induced inflammatory responses.

78

## 79 **Materials and methods**

### 80 **Bacterial culture and gDNA purification**

81 *P. acidilactici* K10 and *P. acidilactici* HW01, which were isolated from kimchi and malt (Ahn  
82 et al., 2017; Kwon et al., 2002), were maintained in Man–Rogosa–Sharpe (MRS) medium  
83 (Neogen, Lansing, MI, USA) at 37°C. The gDNAs of *P. acidilactici* K10 and *P. acidilactici*  
84 HW01 (K10 gDNA and HW01 gDNA, respectively) were extracted using the Wizard®  
85 Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacturer’s  
86 instructions, with some modifications. In brief, bacterial pellets were harvested by  
87 centrifugation at 13,000 × g for 10 min and extensively washed with phosphate-buffered saline  
88 (PBS). The bacterial pellets were resuspended in 480 µL of 50 mM EDTA and 120 µL of  
89 lysozyme (10 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) and incubated at 37°C for 30 min.  
90 After centrifuging at 13,000 × g for 10 min, nuclei lysis solution (600 µL) was added to the  
91 pellets and incubated at 80°C for 5 min to lyse the cell membrane. RNase solution (3 µL) was  
92 then added to the lysates, which were mixed by inverting the tubes five times and then  
93 incubated at 37°C for 40 min. Protein precipitation solution (200 µL) was added to the mixture  
94 and incubated on ice for 5 min to purify the gDNA. After centrifuging at 13,000 × g for 3 min,  
95 the supernatants were transferred to a clean microtube and gently mixed with 600 µL of  
96 isopropanol. After centrifuging at 13,000 × g for 3 min, the supernatants were removed and the  
97 remaining pellets were washed with 70% ethanol. Finally, the ethanol was discarded and the

98 pellets containing gDNA were rehydrated by adding DNA rehydration solution. The  
99 concentration and purity of gDNA were determined using a NanoDrop spectrophotometer (ND-  
100 1000, NanoDrop Technologies, Hampton, NH, USA).

101

## 102 **Cell culture**

103 RAW 264.7 cells were obtained from the American Type Culture Collection (ATCC; Manassas,  
104 VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM; Welgene,  
105 Gyeongsan, Korea) containing 10% heat-inactivated fetal bovine serum (Gibco, Burlington,  
106 ON, Canada), 100 U/mL penicillin, and 100 µg/mL streptomycin (HyClone, Logan, UT, USA)  
107 at 37°C in a 5% CO<sub>2</sub>-humidified incubator.

108

## 109 **Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)**

110 RAW 264.7 cells ( $1 \times 10^5$  cells/mL) were plated on a 12-well culture plate and incubated at  
111 37°C for 24 h. The cells were pretreated with K10 gDNA or HW01 gDNA (1 µg/mL) for 3, 9,  
112 or 15 h and stimulated with 1 µg/mL of *P. gingivalis* LPS for 3 h. In a separate experiment,  
113 RAW 264.7 cells ( $1 \times 10^5$  cells/mL) were plated on a 12-well culture plate and incubated at  
114 37°C for 24 h. The cells were pretreated with various concentrations of K10 gDNA or HW01  
115 gDNA (0.1, 1, and 10 µg/mL) for 15 h and stimulated with 1 µg/mL of *P. gingivalis* LPS for 3  
116 h. Subsequently, spent culture supernatants were discarded and total RNA was extracted from  
117 the cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the  
118 manufacturer's instructions. Total RNA was reversed transcribed to complementary DNA  
119 (cDNA) using random hexamers and reverse transcriptase (Promega). cDNA was amplified by

120 qPCR with SYBR Green Real-Time PCR Master Mix (Toyobo, Osaka, Japan) using the  
121 StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Specific  
122 genes responsible for inflammatory responses, namely those encoding interleukin (IL)-1 $\beta$ , IL-  
123 6, and monocyte chemoattractant protein (MCP)-1, were amplified under the following  
124 conditions: denaturation at 95°C for 10 s, amplification for 40 cycles at 95°C for 5 s and 60°C  
125 for 31 s. The sequences of specific primers were as follows: IL-1 $\beta$ , forward, 5'-  
126 CTCACAAGCAGAGCACAAGC-3' and reverse, 5'-TCTTGGCCGAGGACTAAGGA-3';  
127 IL-6, forward, 5'-TCCTACCCCAATTTCCAATGCT-3' and reverse, 5'-  
128 TCTGACCACAGTGAGGAATGTC-3'; MCP-1, forward, 5'-  
129 AGCCAACTCTCACTGAAGCC-3' and reverse, 5'-TCTCCAGCCTACTCATTGGGA-3';  
130 and  $\beta$ -actin, forward, 5'-TACAGCTTCACCACCACAGC-3' and reverse, 5'-  
131 GGAAAAGAGCCTCAGGGCAT-3'. The relative mRNA expression levels of IL-1 $\beta$ , IL-6,  
132 and MCP-1 were normalized to that of  $\beta$ -actin using the  $2^{-\Delta\Delta Ct}$  method.

133

#### 134 **Enzyme-linked immunosorbent assay (ELISA)**

135 RAW 264.7 cells ( $1 \times 10^5$  cells/mL) were plated on a 96-well culture plate and incubated at  
136 37°C for 24 h. The cells were pretreated with 1  $\mu$ g/mL of K10 gDNA or HW01 gDNA at 37°C  
137 for 15 h and stimulated with *P. gingivalis* LPS (1  $\mu$ g/mL) at 37°C for further 24 h. Subsequently,  
138 spent culture supernatants were collected and the secretion levels of IL-1 $\beta$ , IL-6, and MCP-1  
139 were measured using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA),  
140 according to the manufacturer's instructions.

141

## 142 **Western blot analysis**

143 RAW 264.7 cells ( $1 \times 10^5$  cells/mL) were plated on a 6-well culture plate and incubated at 37°C  
144 for 24 h. The cells were pretreated with 1 µg/mL of K10 gDNA or HW01 gDNA at 37°C for  
145 15 h and stimulated with *P. gingivalis* LPS (1 µg/mL) at 37°C for 30 min. The cells were then  
146 washed with PBS and lysed with a lysis buffer (1 M HEPES, 1 M NaCl, 1% IGEPAL®-CA 630,  
147 0.75% sodium deoxycholate, and 10% glycerol) containing protease and phosphatase inhibitors.  
148 Equal amounts of proteins were separated by 10% sodium dodecyl sulfate–polyacrylamide gel  
149 electrophoresis and electrotransferred to polyvinylidene difluoride membranes (Millipore,  
150 Bedford, MA, USA). The membranes were then blocked with 5% skimmed milk in Tris-  
151 buffered saline containing 0.1% Tween 20 (TBST) and incubated with primary antibodies  
152 specific to extracellular signal-regulated kinase (ERK), phosphorylated ERK, p38 kinase,  
153 phosphorylated p38 kinase, c-Jun-N-terminal kinase (JNK), phosphorylated JNK, IκBα (Cell  
154 Signaling Technology, Danvers, MA, USA), or β-actin (Santa Cruz Biotechnology Inc., Santa  
155 Cruz, CA, USA) at 4°C for 15 h. The membranes were washed with TBST and then incubated  
156 with horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology) at room  
157 temperature for 1 h. Immunoreactive proteins were detected using an enhanced  
158 chemiluminescence reagent (Dyne Bio, Seongnam, Korea) and visualized using a C-DiGit blot  
159 scanner (Li-Cor Bioscience, Lincoln, NE, USA).

160

## 161 **Statistical analysis**

162 All experiments were performed thrice. The results are expressed as the means ± standard  
163 deviations. Statistical differences between the appropriate control and gDNA-treated groups  
164 were assessed by performing unpaired two-tailed *t*-tests using GraphPad Prism 5 software

165 (GraphPad Software Inc., La Jolla, CA, USA).

166

## 167 **Results**

### 168 **K10 gDNA and HW01 gDNA inhibit *P. gingivalis* LPS-induced mRNA expression of IL- 169 $1\beta$ , IL-6, and MCP-1**

170 When the cells were pretreated with K10 gDNA and HW01 gDNA for 3 h, the gDNAs did not  
171 inhibit *P. gingivalis*-induced mRNA expression of IL- $1\beta$  (Fig. 1A), IL-6 (Fig. 1B), and MCP-  
172 1 (Fig. 1C). However, when the cells were pretreated with K10 gDNA and HW01 gDNA for 9  
173 h, the gDNAs partially suppressed inflammatory responses. As shown in Fig. 1D, *P. gingivalis*  
174 LPS-induced IL- $1\beta$  mRNA expression was significantly downregulated in the presence of K10  
175 gDNA and HW01 gDNA ( $P < 0.05$ ), whereas IL-6 and MCP-1 mRNA expression was not  
176 inhibited by these gDNAs (Figs. 1E and 1F, respectively). When RAW 264.7 cells were  
177 pretreated with gDNAs for 15 h, the gDNAs significantly inhibited the mRNA expression of  
178 IL- $1\beta$  (Fig. 1G), IL-6 (Fig. 1H), and MCP-1 (Fig. 1I) ( $P < 0.05$ ). As 15 h-pretreatment with  
179 gDNAs effectively inhibited *P. gingivalis* LPS-induced inflammatory responses, all subsequent  
180 experiments were performed using cells pretreated with gDNAs for 15 h.

181

### 182 **K10 gDNA and HW01 gDNA dose-dependently inhibit *P. gingivalis* LPS-induced mRNA 183 expression of IL- $1\beta$ but not that of IL-6 and MCP-1**

184 To assess the inhibitory effect of different concentrations of gDNAs on *P. gingivalis* LPS-  
185 induced inflammatory responses in RAW 264.7 cells, the cells were pretreated with gDNAs

186 (0.1, 1, and 10  $\mu\text{g/mL}$ ) for 15 h and then stimulated with *P. gingivalis* LPS (1  $\mu\text{g/mL}$ ) for 3 h.  
187 As expected, *P. gingivalis* LPS alone induced IL-1 $\beta$  mRNA expression. However, both K10  
188 gDNA and HW01 gDNA dose-dependently inhibited *P. gingivalis* LPS-induced IL-1 $\beta$  mRNA  
189 expression (Figs. 2A and 2D, respectively). Pretreatment with 0.1 and 1  $\mu\text{g/mL}$  of K10 gDNA  
190 and HW01 gDNA significantly inhibited *P. gingivalis* LPS-induced IL-6 mRNA expression ( $P$   
191  $< 0.05$ ) (Figs. 2B and 2E, respectively). However, 10  $\mu\text{g/mL}$  of both gDNAs failed to inhibit *P.*  
192 *gingivalis* LPS-induced IL-6 mRNA expression (Figs. 2B and 2E). Similarly, 0.1 and 1  $\mu\text{g/mL}$   
193 of K10 gDNA significantly inhibited *P. gingivalis* LPS-induced MCP-1 mRNA expression,  
194 whereas 10  $\mu\text{g/mL}$  did not (Fig. 2C). Moreover, 1  $\mu\text{g/mL}$  of HW01 gDNA inhibited *P.*  
195 *gingivalis* LPS-induced MCP-1 expression, whereas 0.1 and 10  $\mu\text{g/mL}$  did not (Fig. 2F).  
196 Therefore, we decided that the optimal concentration of gDNAs to inhibit *P. gingivalis* LPS-  
197 induced inflammatory responses was 1  $\mu\text{g/mL}$  and used this concentration for further analysis.

198

### 199 **K10 gDNA and HW01 gDNA inhibit *P. gingivalis* LPS-induced secretion of IL-1 $\beta$ , IL-6,** 200 **and MCP-1**

201 To further confirm the inhibition of inflammatory responses at the protein level, RAW 264.7  
202 cells were pretreated with gDNAs (1  $\mu\text{g/mL}$ ) for 15 h and then stimulated with *P. gingivalis*  
203 LPS (1  $\mu\text{g/mL}$ ) for 24 h. Consistent with the results of mRNA expression, both gDNAs  
204 significantly inhibited IL-1 $\beta$  (Fig. 3A), IL-6 (Fig.3B), and MCP-1 (Fig. 3C) secretion induced  
205 by *P. gingivalis* LPS ( $P < 0.05$ ). These results indicate that K10 gDNA and HW01 gDNA  
206 effectively inhibit *P. gingivalis* LPS-induced inflammatory responses.

207

## 208 **K10 gDNA and HW01 gDNA alleviate MAPK phosphorylation and NF- $\kappa$ B activation**

209 MAPK pathways, such as ERK 1/2, p38 kinase, JNK, and NF- $\kappa$ B pathways, are known to be  
210 common inflammatory signaling pathways that cause the release of proinflammatory cytokines,  
211 such as IL-1 $\beta$ , and consequently lead to inflammation (Jayakumar et al., 2021). Therefore, the  
212 activation of MAPK and NF- $\kappa$ B was assessed in RAW 264.7 cells pretreated with or without  
213 gDNAs. As shown in Fig. 4, the phosphorylation of ERK 1/2, p38 kinase, and JNK was higher  
214 in RAW 264.7 cells stimulated with *P. gingivalis* LPS than in those not treated with *P. gingivalis*  
215 LPS. However, pretreatment with K10 gDNA and HW01 gDNA abrogated the phosphorylation  
216 of ERK 1/2, p38 kinase, and JNK, indicating that ERK 1/2, p38 kinase, and JNK signaling  
217 pathways were blocked on pretreatment with both these gDNAs and consequently inhibited *P.*  
218 *gingivalis* LPS-induced inflammatory responses. Moreover, inhibitors of NF- $\kappa$ B, such as I $\kappa$ B $\alpha$ ,  
219 are associated with the downregulation of NF- $\kappa$ B (Wang et al., 2020). *P. gingivalis* LPS alone  
220 inhibited I $\kappa$ B $\alpha$  degradation, indicating that the inflammatory responses were augmented by  
221 NF- $\kappa$ B activation. However, pretreatment of RAW 264.7 cells with K10 gDNA or HW01  
222 gDNA (Fig. 4) restored I $\kappa$ B $\alpha$  degradation, suggesting that both these gDNAs attenuated NF-  
223  $\kappa$ B activation, which was associated with *P. gingivalis* LPS-induced inflammatory responses.

224

## 225 **Discussion**

226 Periodontitis is the most prevalent oral disease that is characterized by gingival inflammation  
227 and the loss of connective tissue attachment, resulting in alveolar bone resorption and tooth  
228 loss (Xu et al., 2020). Although the role of probiotics in modulating periodontal diseases is not  
229 fully understood, several studies have reported the protective effects of probiotics, particularly

230 *Lactobacillus* spp., on periodontal diseases based on *in vitro* and *in vivo* analyses (Gatej et al.,  
231 2018; Nguyen et al., 2021). *P. acidilactici* is frequently found in fermented vegetables and  
232 meat-based products and is considered a potential probiotic with antimicrobial, antioxidant,  
233 and immunomodulatory effects (Feng et al., 2016; Papagianni and Anastasiadou, 2009; Song  
234 et al., 2021). Furthermore, the present study demonstrated that K10 gDNA and HW01 gDNA  
235 markedly inhibited *P. gingivalis* LPS-induced inflammatory responses by suppressing MAPK  
236 and NF- $\kappa$ B signaling pathways in RAW 264.7 cells, suggesting that *P. acidilactici* could also  
237 be a potential probiotic that could be beneficial to oral health.

238 Several lactobacilli have been reported to inhibit inflammatory responses induced by  
239 periodontal pathogenic bacteria, such as *P. gingivalis*. Co-culture with *P. gingivalis* and *L.*  
240 *acidophilus* significantly decreased the mRNA and protein expression levels of IL-1 $\beta$ , IL-6,  
241 and IL-8 in gingival epithelial cells in a dose-dependent manner (Zhao et al., 2012). More  
242 recently, mono-infection of gingival epithelial cells with *P. gingivalis* was found to increase the  
243 expression of IL-1 $\beta$  and TNF- $\alpha$ . However, treatment with *L. rhamnosus* Lr-32 or *L. acidophilus*  
244 LA-5 markedly decreased the expression of IL-1 $\beta$  and TNF- $\alpha$  (Albuquerque-Souza et al.,  
245 2019). In fact, *P. acidilactici* has displayed anti-inflammatory activities against various  
246 pathogenic bacteria. We previously found that bacteriocins isolated from *P. acidilactici* K10  
247 and HW01 suppressed IL-8 production in the human intestinal epithelial cell line Caco-2 in  
248 response to *Enterococcus faecalis* infection (Yoon and Kang, 2020). Cell-free supernatants of  
249 *P. acidilactici* TMAB26 effectively inhibited *Klebsiella pneumoniae* LPS-induced IL-6 and  
250 TNF- $\alpha$  mRNA expression in HT-29 cells and peripheral blood mononuclear cells (Barigela and  
251 Bhukya, 2021). However, the antagonistic effect of *P. acidilactici* or its component(s) on *P.*  
252 *gingivalis*-induced inflammatory responses has not been elucidated. In addition, gDNA derived

253 from *Lactobacillus* spp. has been found to have anti-inflammatory properties. For example,  
254 high-frequency oligodeoxynucleotides of *L. casei* gDNA inhibited IL-8 production in Caco-2  
255 cells *in vitro* and alleviated dextran sulfate sodium-induced murine colitis (Hiramatsu et al.,  
256 2014). Consistent with the present findings, pretreatment with *L. rhamnosus* GG gDNA was  
257 found to alleviate mRNA expression levels of inflammatory cytokines in RAW 264.7 cells upon  
258 LPS challenge (Qi et al., 2020). However, whether gDNAs of probiotic strains exhibit anti-  
259 inflammatory effects against oral pathogenic bacteria remains unclear. We found that *P.*  
260 *acidilactici* gDNA can inhibit *P. gingivalis* LPS-induced inflammatory responses.

261 During the development of periodontitis, periodontal pathogens trigger innate immune  
262 responses by releasing various cytokines and chemokines, which play a pivotal role in the  
263 progression of inflammation (Ramadan et al., 2020). Excessive IL-6 production may be  
264 associated with periodontal tissue destruction by inducing matrix metalloproteinase (MMP)-1  
265 secretion during the progression of periodontitis (Sundararaj et al., 2009). In addition, IL-1 $\beta$  is  
266 involved in the production of MMP-1, leading to tissue damage (Cheng et al., 2020). MCP-1  
267 is produced by macrophages and fibroblasts and acts as a chemoattractant for monocytes and  
268 neutrophils (Strecker et al., 2011). Excessive neutrophil activation can result in the production  
269 of toxic compounds and reactive oxygen species that can also affect aggressive periodontitis  
270 (Ramadan et al., 2020). We found that both K10 gDNA and HW01 gDNA significantly  
271 suppressed these cytokines/chemokines by regulating MAPK and NF- $\kappa$ B signaling pathways,  
272 suggesting that they could relieve inflammation and consequently prevent periodontitis.  
273 Although the precise mechanisms by which *P. acidilactici* gDNAs inhibit the production of  
274 cytokines/chemokines responsible for periodontitis are not fully understood, it can be  
275 speculated that cell signaling mediated by toll-like receptor 9 (TLR9) negatively regulates

276 inflammatory responses. TLR9 is a critical receptor for recognizing bacterial DNA  
277 (Chockalingam et al., 2012). Li et al. (2017) reported that TLR9 deficiency enhanced the  
278 activation of NF- $\kappa$ B, resulting in increased IL-1 $\beta$  expression in intestinal epithelial cells.  
279 Moreover, the use of CpG oligodeoxynucleotides as a TLR9 ligand inhibited MCP-1  
280 expression in adipocytes (Thomalla et al., 2019). Although TLR signaling pathways mainly  
281 induce inflammatory responses, TLR9 signaling promotes the accumulation of I $\kappa$ B $\alpha$  in the  
282 cytoplasm, thereby suppressing NF- $\kappa$ B activation (Li et al., 2017). Therefore, TLR9 activation  
283 by *P. acidilactici* gDNAs may negatively regulate intracellular signaling pathways, such as  
284 MAPK and NF- $\kappa$ B pathways, thereby attenuating inflammatory responses.

285

## 286 **Conclusion**

287 In conclusion, the present study demonstrated the inhibitory effect of *P. acidilactici* gDNA on  
288 *P. gingivalis* LPS-induced inflammatory responses. Several probiotic lactobacilli have shown  
289 anti-inflammatory activities against *P. gingivalis*. Our results provide important insights into  
290 the inhibition of periodontal inflammation using *P. acidilactici* gDNA. Thus, *P. acidilactici*  
291 gDNA could be a potential therapeutic option against periodontitis.

292

## 293 **Conflicts of interest**

294 The authors declare that they have no conflict of interest.

295

## 296 **Acknowledgments**

297 This work was supported by the National Research Foundation of Korea (NRF) grant funded

298 by the Korean government (MSIT) (NRF-2020R1A2C1010010). This work was also supported  
299 by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and  
300 Forestry (IPET) through Technology Commercialization Support Program, funded by Ministry  
301 of Agriculture, Food and Rural Affairs (MAFRA) (821028-03-2-HD040).

302

### 303 **Author contributions**

304 Conceptualization: Choi YH, Kim BS, Kang SS. Data curation: Choi YH, Kim BS. Formal  
305 analysis: Choi YH, Kim BS. Methodology: Choi YH, Kim BS. Software: Choi YH, Kim BS.  
306 Validation: Choi YH, Kim BS. Investigation: Choi YH, Kim BS. Writing - original draft: Choi  
307 YH. Writing - review & editing: Choi YH, Kang SS.

308

### 309 **Ethics Approval**

310 This article does not require IRB/IACUC approval because there are no human and animal  
311 participants.

312

### 313 **References**

314 Ahn HW, Kim JS, Kim WJ. 2017. Isolation and characterization of bacteriocin-producing  
315 *Pediococcus acidilactici* HW01 from malt and its potential to control beer spoilage  
316 lactic acid bacteria. Food Control 80:59-66.

317 Albuquerque-Souza E, Balzarini D, Ando-Sugimoto ES, Ishikawa KH, Simionato MR,  
318 Holzhausen M, Mayer MP. 2019. Probiotics alter the immune response of gingival  
319 epithelial cells challenged by porphyromonas gingivalis. J Periodontal Res 54:115-127.

320 Barigela A, Bhukya B. 2021. Probiotic *Pediococcus acidilactici* strain from tomato pickle  
321 displays anti-cancer activity and alleviates gut inflammation *in vitro*. 3 Biotech 11:23.

322 Bostanci N, Belibasakis GN. 2012. *Porphyromonas gingivalis*: An invasive and evasive  
323 opportunistic oral pathogen. FEMS Microbiol Lett 333:1-9.

324 Cheng R, Wu Z, Li M, Shao M, Hu T. 2020. Interleukin-1 $\beta$  is a potential therapeutic target for  
325 periodontitis: A narrative review. Int J Oral Sci 12:2.

326 Chockalingam A, Rose WA, Hasan M, Ju C-H, Leifer CA. 2012. Cutting edge: A TLR9  
327 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine  
328 production. J Immunol 188:527-530.

329 Chugh B, Kamal-Eldin A. 2020. Bioactive compounds produced by probiotics in food products.  
330 Curr Opin Food Sci 32:76-82.

331 Doron S, Snyderman DR. 2015. Risk and safety of probiotics. Clin Infect Dis 60 Suppl 2:S129-  
332 S134.

333 Feng J, Wang L, Zhou L, Yang X, Zhao X. 2016. Using *in vitro* immunomodulatory properties  
334 of lactic acid bacteria for selection of probiotics against *Salmonella* infection in broiler  
335 chicks. PLoS One 11:e0147630.

336 Gatej SM, Marino V, Bright R, Fitzsimmons TR, Gully N, Zilm P, Gibson RJ, Edwards S,  
337 Bartold PM. 2018. Probiotic *Lactobacillus rhamnosus* gg prevents alveolar bone loss  
338 in a mouse model of experimental periodontitis. J Clin Periodontol 45:204-212.

339 Kim CH, Kim HG, Kim JY, Kim NR, Jung BJ, Jeong JH, Chung DK. 2012. Probiotic genomic  
340 DNA reduces the production of pro-inflammatory cytokine tumor necrosis factor-alpha.  
341 FEMS Microbiol Lett 328:13-19.

342 Hiramatsu Y, Satho T, Hyakutake M, Irie K, Mishima K, Miake F, Kashige N. 2014. The anti-  
343 inflammatory effects of a high-frequency oligodeoxynucleotide from the genomic DNA

344 of *Lactobacillus casei*. Int Immunopharmacol 23:139-147.

345 How KY, Song KP, Chan KG. 2016. *Porphyromonas gingivalis*: An overview of  
346 periodontopathic pathogen below the gum line. Front Microbiol 7:53.

347 Jayakumar T, Lin KC, Chang CC, Hsia CW, Manubolu M, Huang WC, Sheu JR, Hsia CH.  
348 2021. Targeting MAPK/NF- $\kappa$ B pathways in anti-inflammatory potential of  
349 rutaecarpine: Impact on Src/FAK-mediated macrophage migration. Int J Mol Sci 23:92.

350 Kwon DY, Koo MS, Ryoo CR, Kang CH, Min KH, Kim WJ. 2002. Bacteriocin produced by  
351 *Pediococcus* sp. In Kimchi and its characteristics. J Microbiol Biotechnol 12:96-105.

352 Lebeer S, Vanderleyden J, De Keersmaecker SC. 2010. Host interactions of probiotic bacterial  
353 surface molecules: Comparison with commensals and pathogens. Nat Rev Microbiol  
354 8:171-184.

355 Lee DH, Kim BS, Kang SS. 2020. Bacteriocin of *Pediococcus acidilactici* HW01 inhibits  
356 biofilm formation and virulence factor production by *Pseudomonas aeruginosa*.  
357 Probiotics Antimicrob Proteins 12:73-81.

358 Lee HB, Kim KH, Kang GA, Lee KG, Kang SS. 2022. Antibiofilm, antiadhesive and anti-  
359 invasive activities of bacterial lysates extracted from *Pediococcus acidilactici* against  
360 *Listeria monocytogenes*. Foods 11:2948.

361 Li Y, Liu M, Zuo Z, Liu J, Yu X, Guan Y, Zhan R, Han Q, Zhang J, Zhou R, Sun R, Tian Z,  
362 Zhang C. 2017. TLR9 regulates the NF- $\kappa$ B-NLRP3-IL-1 $\beta$  pathway negatively in  
363 *Salmonella*-induced NKG2D-mediated intestinal inflammation. J Immunol 199:761-  
364 773.

365 Moon Y-J, Baik S-H, Cha Y-S. 2014. Lipid-lowering effects of *Pediococcus acidilactici* M76  
366 isolated from Korean traditional makgeolli in high fat diet-induced obese mice.  
367 Nutrients 6:1016-1028.

368 Nguyen T, Brody H, Radaic A, Kapila Y. 2021. Probiotics for periodontal health-current  
369 molecular findings. *Periodontol 2000* 87:254-267.

370 Papagianni M, Anastasiadou S. 2009. Pediocins: The bacteriocins of pediococci. Sources,  
371 production, properties and applications. *Microb Cell Fact* 8:3.

372 Qi SR, Cui YJ, Liu JX, Luo X, Wang HF. 2020. *Lactobacillus rhamnosus* GG components,  
373 SLP, gDNA and CpG, exert protective effects on mouse macrophages upon  
374 lipopolysaccharide challenge. *Lett Appl Microbiol* 70:118-127.

375 Ramadan DE, Hariyani N, Indrawati R, Ridwan RD, Diyatri I. 2020. Cytokines and  
376 chemokines in periodontitis. *Eur J Dent* 14:483-495.

377 Saini R, Marawar PP, Shete S, Saini S. 2009. Periodontitis, a true infection. *J Glob Infect Dis*  
378 1:149-150.

379 Seo HJ, Kang SS. 2020. Inhibitory effect of bacteriocin produced by *Pediococcus acidilactici*  
380 on the biofilm formation of *Salmonella* Typhimurium. *Food Control* 117:107361.

381 Song YR, Lee CM, Lee SH, Baik SH. 2021. Evaluation of probiotic properties of *Pediococcus*  
382 *acidilactici* M76 producing functional exopolysaccharides and its lactic acid  
383 fermentation of black raspberry extract. *Microorganisms* 9:1364.

384 Strecker JK, Minnerup J, Gess B, Ringelstein EB, Schabitz WR, Schilling M. 2011. Monocyte  
385 chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1 $\beta$  and G-CSF  
386 after transient focal ischemia in mice. *PLoS One* 6:e25863.

387 Sundararaj KP, Samuvel DJ, Li Y, Sanders JJ, Lopes-Virella MF, Huang Y. 2009. Interleukin-  
388 6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1  
389 expression by U937 macrophages in coculture: Cross-talking between fibroblasts and  
390 u937 macrophages exposed to high glucose. *J Biol Chem* 284:13714-13724.

391 Thomalla M, Schmid A, Neumann E, Pfefferle PI, Muller-Ladner U, Schaffler A, Karrasch T.

392 2019. Evidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in  
393 adipocytes. *J Endocrinol* 240:325-343.

394 Wang X, Peng H, Huang Y, Kong W, Cui Q, Du J, Jin H. 2020. Post-translational modifications  
395 of I $\kappa$ B $\alpha$ : The state of the art. *Front Cell Dev Biol* 8:574706.

396 Winning L, Linden GJ. 2015. Periodontitis and systemic disease. *BDJ Team* 2:15163.

397 Xu W, Zhou W, Wang H, Liang S. 2020. Roles of *Porphyromonas gingivalis* and its virulence  
398 factors in periodontitis. *Adv Protein Chem Struct Biol* 120:45-84.

399 Yoon JW, Kang SS. 2020. *In vitro* antibiofilm and anti-inflammatory properties of bacteriocins  
400 produced by *Pediococcus acidilactici* against *Enterococcus faecalis*. *Foodborne Pathog*  
401 *Dis* 17:764-771.

402 Zhao J-J, Feng X-P, Zhang X-L, Le K-Y. 2012. Effect of *Porphyromonas gingivalis* and  
403 *Lactobacillus acidophilus* on secretion of IL1 $\beta$ , IL6, and IL8 by gingival epithelial cells.  
404 *Inflammation* 35:1330-1337.

405

406

407

408

409

410

411

412

413 **Figure Legends**

414 **Fig. 1.** Inhibition of mRNA expression of inflammatory mediators by *P. acidilactici* gDNAs in  
415 RAW 264.7 cells stimulated with *P. gingivalis* LPS. RAW 264.7 cells were pretreated with K10  
416 gDNA or HW01 gDNA (1 µg/mL) for 3, 6, or 15 h and then stimulated with *P. gingivalis* LPS  
417 (1 µg/mL) for 3 h. The mRNA expression levels of IL-1β, IL-6, and MCP-1 were determined  
418 using RT-qPCR. The results are expressed as the means ± standard deviations from three  
419 independent experiments. The asterisk (\*) indicates a statistically significant difference ( $P <$   
420 0.05) compared with the control. LPS: *P. gingivalis* LPS; K10: K10 gDNA; HW01: HW01  
421 gDNA.

422  
423 **Fig. 2.** Inhibition of mRNA expression of inflammatory mediators by various concentrations  
424 of *P. acidilactici* gDNAs in RAW 264.7 cells stimulated with *P. gingivalis* LPS. RAW 264.7  
425 cells were pretreated with K10 gDNA or HW01 gDNA (0.1, 1, and 10 µg/mL) for 15 h and  
426 then stimulated with *P. gingivalis* LPS (1 µg/mL) for 3 h. The mRNA expression levels of IL-  
427 1β, IL-6, and MCP-1 were determined using RT-qPCR. The results are expressed as the means  
428 ± standard deviations from three independent experiments. The asterisk (\*) indicates a  
429 statistically significant difference ( $P < 0.05$ ) compared with the control. LPS: *P. gingivalis* LPS;  
430 K10: K10 gDNA; HW01: HW01 gDNA.

431  
432 **Fig. 3.** Inhibition of protein expression of inflammatory mediators by *P. acidilactici* gDNAs in  
433 RAW 264.7 cells stimulated with *P. gingivalis* LPS. RAW 264.7 cells were pretreated with K10  
434 gDNA or HW01 gDNA (1 µg/mL) for 15 h and then stimulated with *P. gingivalis* LPS (1 µg/mL)

435 for 24 h. The secretion levels of IL-1 $\beta$ , IL-6, and MCP-1 were determined using ELISA. The  
436 results are expressed as the means  $\pm$  standard deviations from three independent experiments.  
437 The asterisk (\*) indicates a statistically significant difference ( $P < 0.05$ ) compared with the  
438 control. LPS: *P. gingivalis* LPS; K10: K10 gDNA; HW01: HW01 gDNA.

439

440 **Fig. 4.** Inhibition of MAPK phosphorylation and NF- $\kappa$ B activation by *P. acidilactici* gDNAs  
441 in RAW 264.7 cells stimulated with *P. gingivalis* LPS. RAW 264.7 cells were pretreated with  
442 K10 gDNA or HW01 gDNA (1  $\mu$ g/mL) for 15 h and then stimulated with *P. gingivalis* LPS (1  
443  $\mu$ g/mL) for 30 min. The phosphorylation of ERK 1/2, p38, and JNK and the degradation of  
444 I $\kappa$ B $\alpha$  were assessed using western blot analysis.

445

446

447

448

449


450

451

452

453

454



455

456

457

458

459

Figure 1




Figure 2

460

461

462

463

464




465

466

467

468

469

**A****B****C**

470

471

472

473

474

475

476

477

478

479

480


481

482

483

Figure 3

LPS (1 µg/mL)	-	+	+	+
K10 (1 µg/mL)	-	-	+	-
HW01 (1 µg/mL)	-	-	-	+



484

485

Figure 4